Compare Amphastar Pharmaceuticals Inc (AMPH) vs Fastly Inc (FSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Fastly Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Fastly Inc trades at $19.5 (market cap $3.07B). The key difference: Fastly Inc is far larger — about 3.7× Amphastar Pharmaceuticals Inc's market cap, and Fastly Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | FSLY | |
|---|---|---|
Market Cap | $826.08M | $3.07B |
Sector | Health | Technology |
52-Week High | $30.81 | $33.50 |
52-Week Low | $16.87 | $6.36 |
Enterprise Value | $1.22B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Fastly (FSLY) trades at $19.59, down 3.64% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue growth accelerated to 20% year-over-year in Q1 2026, though the company remains unprofitable with a net margin of -19.5% in 2025. Analyst consensus is mixed with a $25.80 price target, while recent news highlights partnerships and AI-driven compute growth.
The outlook is cautiously optimistic: continued revenue expansion and margin improvement offer upside potential, but persistent losses and competitive pressures pose risks. Investors should weigh the stock's discounted valuation against execution challenges in a crowded edge cloud market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
